Since Friday, Morphic Therapeutic MORF shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results at United ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min With two Big Pharmas abandoning ...

Monday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion. Morphic is a biopharmaceutical company ...

Johnson & Johnson’s Janssen subsidiary has terminated its research collaboration and option agreement with Morphic Therapeutic, the company announced in a filing with the Securities and Exchange ...

-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on target in EMERALD-2 Phase 2b trial of ...

WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious ...

Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and ...

NORTH CHICAGO, Ill. and WALTHAM, Mass., Oct. 18, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Morphic Therapeutic, a biotechnology company ...

A live webcast of the panel discussion and fireside chat at the TD Cowen 44 th Annual Health Care Conference will be available on the Investor section of Morphic’s website at www.morphictx.com. An ...

WALTHAM, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ...

First orally available integrin inhibitor from MInT Platform to enter the clinic MORF-057, inhibitor of α 4 β 7 integrin, in development to treat inflammatory bowel disease Phase 1 programto assess ...